Kounis Syndrome Market Size, Share, and COVID-19 Impact Analysis By Drug Class (Antihistamines, Anti-Inflammatory Drugs, Alpha- and Beta-Adrenergic Agonists, and Vasodilators), By Distribution Channel (Hospital Pharmacies, and Online & Retail Pharmacies), and Regional Forecast, 2025-2032

Kounis syndrome is a condition triggered by an allergic reaction to certain drugs leading to a heart attack. There is an increase in the prevalence of heart diseases among the general population across the world. An unhealthy diet, lack of physical activity, consumption of alcohol and tobacco, etc., are among the leading factors responsible for the increasing risk of heart disease.

• According to the data published by the Centers for Disease Control and Prevention (CDC) in 2022, it was reported that about 20.1 million adults of age 20 and older have coronary artery disease, which is around 7.2% in the U.S.

The major players in the market are focusing on investing in clinical studies to develop effective treatment options to support patients with Kounis syndrome worldwide. All these factors are responsible for driving the market growth.

However, the high costs associated with the cardiology devices, the high treatment costs, the unavailability of information, the lack of diagnosis of the syndrome, and the support provided for Kounis syndrome in countries like South Africa, Brazil, India, etc., are responsible for restricting the market growth.

Impact of COVID-19 on the Kounis Syndrome Market

The COVID-19 pandemic had a negative impact on the Kounis syndrome market. This is due to the decreased production, disrupted supply chains, and the utilization of healthcare resources to manage COVID-19, which affected the market during the pandemic.

The decrease in diagnostic procedures, like cardiac catheterization, myocardial biopsy, etc., was observed due to fewer patient visits and hospitalizations during the pandemic. Also, the limited availability of physicians during the pandemic resulted in a decline in the number of cardiac procedures performed worldwide.

• According to the data published by General Electric Company in 2021, it was reported in Spain, around 57.0% fewer diagnostic procedures were observed during the pandemic.

Key Insights

The report will cover the following key insights:

• Incidence of Myocardial Infarctions, By Key Countries.
• Technological Advancements in the Kounis Syndrome Market.
• Key Industry Developments- Mergers, Partnerships, & Acquisitions.
• Impact of COVID-19 on the Market.

Analysis by Treatment

Based on drug class, the market is segmented into antihistamines, anti-inflammatory drugs, alpha- and beta-adrenergic agonists, and vasodilators. The increasing focus of key players in partnering with other companies to develop new treatment options for Kounis syndrome. The robust focus on research & development investments to conduct clinical trials to know the efficiency of drugs in treating this syndrome and the companies expanding their pipeline portfolio is responsible for driving the growth of anti-inflammatory drugs.

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America dominates the Kounis syndrome market due to the increasing focus of major industry players on research and development investments for clinical studies on various treatment options and the direct presence of major players in the U.S. Also, this region's rising prevalence of coronary artery diseases is further responsible for the market's growth.

• According to the data published by CDC, one person dies every 34 seconds due to cardiovascular disease in the U.S.

The Asia Pacific is anticipated to reach the highest CAGR during the forecast period. This is due to the majority of heat-related deaths globally occurring in Asia, resulting in the increasing demand for unique treatment options in this region.

• According to the data published by the Australian Institute of Health and Welfare (AIHW) in 2021, it was reported that about 571,000 Australians aged 18 and over had coronary heart disease, affecting 1 in 9, i.e., 11.0% of adults aged 75 and over.

Key Players Covered

The report will include the profiles of key players such as Verily, Pfizer Inc., CVRx, Inc., Johnson & Johnson Services, Inc., BlueRock Therapeutics, and others.

Segmentation

Key Industry Developments

• September 2020: CID S.p.A., part of the Alvimedica company, started a new research program co-funded by Piedmont Region. This program will help the company to develop new products for vascular disease treatment.
• January 2020: BlueRock Therapeutics collaborated with Ncardia to obtain manufacturing rights of induced pluripotent stem cell (iPSC) derived cardiomyocytes for therapeutic use. iPSC is used to help advance potential cell therapies for cardiac diseases.
• May 2019: Verily focused on developing lipid-based nanoparticle technology to treat coronary artery disease.
• May 2019: iVascular introduced the innoVasc program to promote advanced treatment options for diseases of the cardiovascular system.